ArticleDrugs & aging2026
Real-World Persistence After Starting Bictegravir- or Dolutegravir-Based Regimens Among Adults Aged ≥50 Years with HIV in the United States.
Article in Drugs & aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPersistence and adherence to antiretroviral therapy (ART) are crucial for effective viral suppression and may be impacted by comorbidities and polypharmacy in older people with HIV (PWH). This study compared ART persistence among treatment-naive and treatment-experienced PWH aged ≥50 years who received bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG)-based regimens.
methodsThis observational, retrospective study utilized US medical and pharmacy claims data from HealthVerity Marketplace (1 January 2015 to 29 February 2024). PWH were aged ≥50 years and received B/F/TAF, dolutegravir/lamivudine (DTG/3TC), dolutegravir/abacavir/lamivudine (DTG/ABC/3TC), or DTG-based multitablet regimens (MTRs). Baseline characteristics were balanced using inverse probability of treatment weighting. Time to nonpersistence (i.e., discontinuation or switching) was depicted using Kaplan-Meier plots. Risk of nonpersistence was modeled using weighted Cox proportional hazards models.
resultsOverall, 32,448 PWH aged ≥50 years were included in the analysis; 77% were treatment experienced. Among treatment-experienced PWH, those who received B/F/TAF had significantly lower adherence during the baseline period than those who received DTG/3TC and significantly higher adherence during the baseline period than those who received DTG/ABC/3TC and DTG-based MTRs. Nonetheless, persistence on B/F/TAF was longer than DTG/ABC/3TC and DTG-based MTRs in both subgroups. Treatment-naive and treatment-experienced PWH who received B/F/TAF had significantly lower hazards of nonpersistence versus those who received DTG/ABC/3TC and DTG-based MTRs (all p < 0.001), as did treatment-naive PWH who received B/F/TAF versus DTG/3TC (p = 0.031).
conclusionsB/F/TAF was associated with higher persistence than other ART regimens among older PWH. Findings underscore the importance of tailored ART selection to address the unique challenges faced by older PWH.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.